BMRN — BIOMARIN PHARMACEUTICAL INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1048477 ·
Last close
$58.51
Market Cap
$11.33B
52W High
$70.98
52W Low
$49.26
ADV30
2,447,910
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,024,646,000 | 819,230,000 | 205,647,000 | -122,831,000 | 11,569,231,000 | 736,007,000 | 5,313,199,000 |
| Jun 2026 | 989,708,000 | 786,913,000 | 110,969,000 | 44,762,000 | 11,723,442,000 | 874,005,000 | 5,401,750,000 |
| Mar 2026 | 766,208,000 | 571,209,000 | 129,630,000 | 105,527,000 | 8,591,016,000 | 2,222,435,000 | 2,378,909,000 |
| Dec 2025 | 874,565,000 | 598,856,000 | -44,603,000 | -46,573,000 | 7,594,022,000 | 1,311,679,000 | 1,507,023,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$676,618,000
Investing CF
$-4,725,698,000
Financing CF
$3,535,877,000
CapEx
$-122,313,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.10
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$181,664,000
Inventory
$1,796,069,000
Receivables
$1,076,355,000
ST Investments
$0
EBIT TTM
$180,324,000
Pretax Income TTM
$43,665,000
Interest Exp TTM
$136,659,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,655,127,040
EBITDA
$854,987,008
Free Cash Flow
$-16,042,000
Enterprise Value
$14,306,919,424
Total Cash
$736,006,976
Total Debt
$4,190,210,048
Shares Out
193,694,734
Trailing EPS
$-0.10
Book Value
$32.30
ROE
-0.3%
ROA
3.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,221,253,000 | 409,495,000 | 348,901,000 | 7,594,022,000 | 1,507,023,000 | 6,086,999,000 | 827,994,000 |
| Dec 2024 | 2,853,915,000 | 474,239,000 | 426,859,000 | 6,988,940,000 | 1,330,950,000 | 5,657,990,000 | 572,841,000 |
| Dec 2023 | 2,419,226,000 | 185,780,000 | 167,645,000 | 6,841,603,000 | 1,890,054,000 | 4,951,549,000 | 159,259,000 |
| Dec 2022 | 2,096,039,000 | 57,410,000 | 141,561,000 | 6,375,074,000 | 1,771,918,000 | 4,603,156,000 | 175,902,000 |
TTM Snapshot
Revenues TTM
$3,406,614,000
NetIncome TTM
$72,972,000
OpCashFlow TTM
—
Assets (Latest)
$11,723,442,000
Forward EPS
$6.37
Max Pain — expiry 2026-12-18
max pain strike: $60.00 · spot: $61.43 · call oi: 3,336 · put oi: 1,701Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RDY | DR REDDYS LABORATORIES LTD | $12.32B | $14.79 | — |
| ELAN | Elanco Animal Health Inc | $12.92B | $25.85 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $9.80B | $421.99 | — |
| TGTX | TG THERAPEUTICS, INC. | $9.48B | $62.71 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.91B | $93.81 | — |
News headlines (Yahoo Finance, 1h cache)
How Investors Are Reacting To BioMarin (BMRN) Acquired Drug Growth Prospects
2026-11-18 23:18 · Yahoo
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
2026-11-16 13:12 · Yahoo
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
2026-11-12 01:12 · Yahoo
BioMarin to Participate in Upcoming Investor Conferences
2026-11-04 14:00 · Yahoo
BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
2026-11-04 03:02 · Yahoo
BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
2026-11-03 11:19 · Yahoo
BioMarin (BMRN) Q3 2026 Earnings Call Transcript
2026-11-03 04:43 · Yahoo
BioMarin Pharmaceutical Q3 Earnings Call Highlights
2026-11-03 02:14 · Yahoo
BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
2026-11-03 02:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.